Shiaw-Yih Lin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4233484/publications.pdf

Version: 2024-02-01

63 papers	3,649 citations	147801 31 h-index	138484 58 g-index
65 all docs	65 docs citations	65 times ranked	6314 citing authors

#	Article	IF	Citations
1	Multiple Tumor Suppressor Pathways Negatively Regulate Telomerase. Cell, 2003, 113, 881-889.	28.9	400
2	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell, 2018, 33, 401-416.e8.	16.8	215
3	Genome-wide transcriptome profiling of homologous recombination DNA repair. Nature Communications, 2014, 5, 3361.	12.8	182
4	Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function. Cancer Cell, 2009, 15, 304-314.	16.8	175
5	BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nature Cell Biology, 2009, 11, 865-872.	10.3	175
6	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine, 2017, 9, .	12.4	174
7	BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1â€“Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15105-15109.	7.1	160
8	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell, 2019, 35, 851-867.e7.	16.8	156
9	Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nature Cell Biology, 2015, 17, 1158-1168.	10.3	154
10	BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 2006, 10, 145-157.	16.8	137
11	TRF2 functions as a protein hub and regulates telomere maintenance by recognizing specific peptide motifs. Nature Structural and Molecular Biology, 2009, 16, 372-379.	8.2	118
12	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature Communications, 2020, 11, 2135.	12.8	114
13	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 1699-1712.	7.0	95
14	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nature Communications, 2018, 9, 1317.	12.8	94
15	BRIT1/MCPH1 Is Essential for Mitotic and Meiotic Recombination DNA Repair and Maintaining Genomic Stability in Mice. PLoS Genetics, 2010, 6, e1000826.	3.5	86
16	Chromodomain Helicase DNA-binding Protein 4 (CHD4) Regulates Homologous Recombination DNA Repair, and Its Deficiency Sensitizes Cells to Poly(ADP-ribose) Polymerase (PARP) Inhibitor Treatment. Journal of Biological Chemistry, 2012, 287, 6764-6772.	3.4	85
17	DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment. World Journal of Surgery, 2009, 33, 661-666.	1.6	77
18	DNA damage and breast cancer. World Journal of Clinical Oncology, 2011, 2, 329.	2.3	69

#	Article	IF	Citations
19	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell, 2020, 37, 371-386.e12.	16.8	68
20	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clinical Cancer Research, 2023, 27, 852-864.	7.0	61
21	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. Npj Systems Biology and Applications, 2017, 3, 8.	3.0	55
22	Connecting the Dots: From DNA Damage and Repair to Aging. International Journal of Molecular Sciences, 2016, 17, 685.	4.1	53
23	Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle, 2008, 7, 2225-2233.	2.6	52
24	The DNA damage response: Balancing the scale between cancer and ageing. Aging, 2010, 2, 900-907.	3.1	52
25	Role of DNA repair defects in predicting immunotherapy response. Biomarker Research, 2020, 8, 23.	6.8	47
26	Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention. Experimental Hematology and Oncology, 2013, 2, 29.	5.0	40
27	Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle, 2015, 14, 2323-2332.	2.6	38
28	PARP inhibitors synergize with gemcitabine by potentiating DNA damage in nonâ€smallâ€cell lung cancer. International Journal of Cancer, 2019, 144, 1092-1103.	5.1	38
29	Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World Journal of Clinical Oncology, 2011, 2, 73.	2.3	38
30	Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. Cell Reports, 2018, 23, 2095-2106.	6.4	37
31	BRIT1/MCPH1: A Guardian of Genome and an Enemy of Tumors. Cell Cycle, 2006, 5, 2579-2583.	2.6	35
32	Multiple Roles of BRIT1/MCPH1 in DNA Damage Response, DNA Repair, and Cancer Suppression. Yonsei Medical Journal, 2010, 51, 295.	2.2	32
33	DNA Damage Response Is Suppressed by the High Cyclin-dependent Kinase 1 Activity in Mitotic Mammalian Cells. Journal of Biological Chemistry, 2011, 286, 35899-35905.	3.4	31
34	ZNF668 Functions as a Tumor Suppressor by Regulating p53 Stability and Function in Breast Cancer. Cancer Research, 2011, 71, 6524-6534.	0.9	26
35	Spontaneous tumor regression following COVID-19 vaccination. , 2022, 10, e004371.		26
36	TUSC4 Functions as a Tumor Suppressor by Regulating BRCA1 Stability. Cancer Research, 2015, 75, 378-386.	0.9	24

#	Article	IF	Citations
37	Exploring Rak tyrosine kinase function in breast cancer. Cell Cycle, 2009, 8, 2360-2364.	2.6	20
38	Zinc finger protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage. Cell Cycle, 2013, 12, 2033-2041.	2.6	19
39	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Science Translational Medicine, 2021, 13, eabe6201.	12.4	19
40	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung Journal of Medical Sciences, 2021, 37, 448-458.	1.9	15
41	Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Molecular Cancer Therapeutics, 2021, 20, 1257-1269.	4.1	15
42	New insights into tumor dormancy: Targeting DNA repair pathways. World Journal of Clinical Oncology, 2015, 6, 80.	2.3	15
43	BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis, 2013, 34, 2271-2280.	2.8	13
44	BRIT1/MCPH1 is a multifunctional DNA damage responsive protein mediating DNA repair-associated chromatin remodeling. Cell Cycle, 2009, 8, 3071-3072.	2.6	12
45	Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression. Oncogene, 2019, 38, 3919-3931.	5.9	11
46	Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Research, 2020, 80, 4854-4867.	0.9	11
47	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
48	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances, 2017, 3, e1600957.	10.3	10
49	MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media and Molecular Imaging, 2017, 2017, 1-11.	0.8	9
50	The role of Rak in the regulation of stability and function of BRCA1. Oncotarget, 2017, 8, 86799-86815.	1.8	9
51	Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress. Molecular Cancer Research, 2020, 18, molcanres.0777.2019.	3.4	8
52	The linkage of chromatin remodeling to genome maintenance: Contribution from a human disease gene BRIT1/MCPH1. Epigenetics, 2009, 4, 457-461.	2.7	7
53	CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling. American Journal of Cancer Research, 2018, 8, 903-914.	1.4	6
54	A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches. International Journal of Molecular Sciences, 2021, 22, 5008.	4.1	3

#	Article	IF	Citations
55	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. AIMS Medical Science, 2016, 3, 386-416.	0.4	3
56	The Tale of CHD4 in DNA Damage Response and Chemotherapeutic Response. Cancer Research and Cellular Therapeutics, 2019, 3, .	0.0	3
57	Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. American Journal of Cancer Research, 2020, 10, 3947-3972.	1.4	3
58	BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. American Journal of Cancer Research, 2020, 10, 1900-1918.	1.4	2
59	BRIT1 Gene. , 2011, , 567-570.		0
60	BRIT1 Gene. , 2015, , 1-4.		0
61	BRIT1 Gene. , 2017, , 699-702.		0
62	CNGPLD: caseâ€“control copy-number analysis using Gaussian process latent difference. Bioinformatics, 2022, , .	4.1	0
63	Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. American Journal of Cancer Research, 2022, 12, 337-354.	1.4	0